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Conclusion: The current study indicates that ADC mapping is 
the most promising MRI technique to predict the tumor 
location in the prostate based on TFA and therefore is 
absolute prerequisite for dose painting approaches in 
advanced adaptive radiotherapy (ART). 
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Purpose or Objective: Oropharyngeal squamous cell 
carcinoma (OPSCC) is one of the fastest growing head and 
neck cancers, for which human papillomavirus (HPV) status 
has been described as a strongly prognostic factor. Overall, 
prognosis is favorable for HPV positive (HPV+) patients, which 
makes this an interesting subgroup for de-escalation 
protocols. An established, non-invasive, imaging biomarker of 
HPV status currently does not exist. Radiomics–the high-
throughput extraction of large amounts of quantitative 
features from medical images–has already been shown to be 
of prognostic value for head and neck cancer. In this study 
we evaluate the use of a Radiomic approach to distinguish 
between HPV+ and HPV negative (HPV-) OPSCC patients. 
 
Material and Methods: A total of 542 patients with OPSCC, 
treated with curative intent between 2005 and 2010 were 
collected for this study. HPV status was determined by p16 
and available for 434 patients. Patients underwent pre-
treatment CT imaging and the tumor volume was manually 
delineated for treatment planning purposes. Images were 
visually assessed for the presence of CT artifacts (e.g. streak 
artifacts due to dental fillings) within the GTV, in which case 
they were excluded from further analysis. In total, 241 
Radiomic features were extracted, comprising: a) first-order 
statistics, b) shape, and c) (multiscale) texture by Laplacian 
of Gaussian filtering. The Radiomic feature space was first 
reduced by selecting cluster medoids after hierarchical 
cluster analysis using correlation (ρ>0.9) as a distance 
measure. Multivariable logistic regression was performed 
using least absolute shrinkage and selection operator (LASSO) 
model selection (100 times 10-fold cross-validated). The area 
under the receiver operator curve (AUC; 500 times 
bootstrapped) was used to assess out-of-sample model 
performance in predicting HPV status. 
 
Results: Out of the patients with known HPV scoring, we 
identified 211 (49%) patients without visible CT artifacts, of 
which 134 were HPV positive. The modeling process resulted 
in an eleven-feature multivariable prediction model. The 
overall receiver operator curve is shown in Figure 1. The 
bootstrapped AUC was on average 0.77 (95% CI: 0.73-0.80). 
 
 
Conclusion: Using a Radiomic approach, we were able to 
distinguish between HPV+ and HPV- OPSCC patients, using 
standard pre-treatment CT imaging. These results require 
further validation, but suggest the potential for a novel 
quantitative Radiomic biomarker of HPV status, facilitating 
personalized treatment selection. 
 
Symposium: Adaptive treatments in the pelvic region  
 
 
SP-0421  
Brachytherapy pelvic and MRI-Linac combination 
C.N. Nomden
1UMC Utrecht, Radiation Oncology, Utrecht, The Netherlands 
1, A.A.C. De Leeuw1, B.W. Raaymakers1, J.J.W. 
Lagendijk1, I.M. Jürgenliemk-Schulz1 
 
MRI guidance for the radiation treatment of patients with 
cancer in the pelvic region has globally increased during the 
last two decades. MRI is used for staging, treatment planning, 
monitoring of treatment response and for disease observation 
during follow up. Consistent and repetitive use of MRI has 
provided insight into tumour and surrounding organ anatomy 
as well as their movements and deformations. In cervical 
cancer treatment, MRI guidance for brachytherapy treatment 
planning and dose delivery allowed better tailoring of the 
dose to the target, with higher tumour doses while sparing 
the organs at risk (OARs). However, the aimed dose for target 
and OARs may differ from the actually delivered dose due to 
movements and deformations of the OARs during HDR or PDR 
treatments. Several single institution reports describe that 
dose uncertainties caused by displacement and deformations 
of OARs are on average small, however individual outliers 
occur. Especially for the rectum higher delivered doses have 
been found in individual patients. In case of HDR 
brachytherapy, re-imaging prior to dose delivery can help to 
detect unfavourable anatomical changes, allowing for 
interventions that might help to stabilize dosimetry and 
prevent morbidity. The availability of MR imaging within the 
brachytherapy suite is an upcoming innovation that supports 
these types of adaptive brachytherapy approaches. The aim 
of the international ‘EMBRACE study’ 
(www.embracestudy.dk) was to introduce MRI based 
brachytherapy in a multicentre setting within a prospective 
observational setting and to correlate DVH parameters with 
outcome. Preliminary results from EMBRACE, from the 
retrospective ‘Retro-EMBRACE’ study 
(www.retroembrace.com) and from several single institution 
reports, revealed an increase in local control due to the use 
of MRI guidance. Brachytherapy treatment allows delivery of 
sterilizing doses to the primary cervical tumour, however, 
lymph node disease is getting the dose delivered by external 
beam radiotherapy treatment (EBRT). The upcoming 
prospective multicentre ‘EMBRACE II study’ will focus on 
advanced Image Guided and Adaptive EBRT (IGART) combined 
with MRI guided intracavitary/interstitial brachytherapy with 
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the aim to improve loco-regional control and survival, 
however not at the expense of treatment related morbidity. 
Besides nodal disease detection, monitoring nodal disease 
during treatment is stil a remaining challenge. Node positions 
and volumes can change during the course of treatment 
asking for EBRT strategies that are able to follow these 
changes in order to allow tight treatment margins. 
Unfortunately the visibility of lymph nodes on cone beam CT 
images is limited and shifted and shrunken lymph nodes can 
be missed. The superior soft tissue contrast of MRI based 
position verification as realized in the concept of integrated 
MRI and linear accelerator (MR-Linac) decreases the 
uncertainties around nodal disease development during the 
course of radiotherapy, allows a more precise definition of 
nowadays accepted elective treatment margins and might 
allow an additional boost to individual lymph nodes . 
Currently, an MR-Linac system is built at the radiation 
oncology department at the UMC Utrecht, bringing the 
ultimate combination of MRI guided brachytherapy, advanced 
adapted external beam treatment with concurrent cisplatin 
based chemotherapy and MR-Linac treatment for nodal 
disease within reach for the treatment of patients with 
advanced cervical cancer. 
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For patients with cervical cancer, despite the improved dose 
conformity enabled by IMRT and VMAT, sparing of bladder, 
rectum and small bowel is still challenging because all organs 
at risk (OAR) in the pelvic area change shape and position on 
a daily basis due to variations in filling. With the introduction 
of cone-beam CT scanners it became possible to observe the 
internal organ variations of patients during each treatment 
fraction. Theoretically, this enables re-adaptation of plans 
according to tumour shrinkage and changes in OAR 
morphology, resulting in reduction of toxicity [1,2] and 
better target coverage. Full online plan adaptation requires 
that re-delineation, re-optimizing of dose distributions and 
repetition of all legally required quality assurance steps 
should be performed in a few minutes. These workload 
intensive procedures would require a high degree of 
automation and workflow-integration that is currently absent 
in off-the-shelf products.  
Nonetheless, by finding a well-balanced compromise between 
full automation and degree of plan adaptation, it is possible 
to apply a simplified scheme of adaptation that provides 
improved treatment. Based on our own experience and that 
of other research groups [3], patients can be divided into two 
groups: the first group consists of patients who show uterus 
motion as a function of bladder filling (called “Movers”) and 
the second group are those patients whose uterus position 
stays relatively stable, regardless of bladder volume (“Non-
Movers”). With a model for the uterus position, a pre-
determined set of plans (library) can be constructed for the 
“Movers” and the most appropriate treatment plan can be 
selected on a daily basis with the help of CBCT scans, while 
for the “Non-Movers” a single plan will suffice.  
The patient specific relation between bladder filling and the 
position of the uterus can be assessed by making a set of CT 
scans with full and empty bladder. A two stage approach, 
consisting of two treatment plans, one for an empty to half 
full and one for half full to full bladder, has been shown to 
give a good level of plan adaptiveness [2], ensuring both a 
good tumor coverage as sparing of the surrounding healthy 
tissue.  
Commercially available clinical software that is designed for 
organ contouring and treatment plan optimization does not 
provide solutions to generate new contours based on a 
motion model that interpolates between two extreme 
(filling) positions of an organ. We developed a MATLAB-based 
tool that allows generating intermediate contours of uterus 
as well as bladder, according to the available bladder 
volumes. Its main purpose was to interpolate linearly 
between two extreme positions and/or filling states of 
patient’s organ contours. Non-rigid deformation between one 
organ position and the other was made by matching the outer 
contour of both structures. To facilitate data handling and 
DICOM import/export options, the Matlab code was 
integrated to 3DSlicer/SlicerRT (Freeware for image 
handling) by using MatlabBridge.  
Our first adaptive patient was treated in October 2016 and in 
this presentation we will discuss our experience we gained 
since then, the challenges we encountered and the risks that 
remain with the implemented procedure. Furthermore, 
dosimetric results of different ART schemes as well as open 
issues like non-rigid dose addition for evaluation will be 
discussed.  
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The standard of care for non-metastasized locally advanced 
rectal cancer is chemo-radiotherapy combined with surgery. 
Sparing the organs at risk (OAR) with the use of state-of-the-
art planning techniques like intensity-modulated radiation 
therapy (IMRT) or volumetric modulated arc therapy (VMAT) 
is compromised by the large population-based margins that 
are necessary to compensate for the shape changes of the 
target volume over the time of treatment. In rectum 
patients, day-to-day variation in rectum and bladder filling 
often causes large deformation of the target volume, 
especially the mesorectal fat (mesorectum), which cannot be 
corrected for with a table adjustment. Minimizing shape 
changes with the use of drinking protocols to manage bladder 
filling or dietary instruction to manage bowel motion have 
been unsuccessful.  
A strategy with multiple plans made prior to treatment 
tailored to a range of possible shapes can mitigate the 
variations in target volume, by selecting the best-fitting plan 
based on daily Cone Beam CT (CBCT) scans. This strategy has 
been successfully applied in the treatment of bladder and 
cervical cancer where bladder filling is the predominant 
factor of shape changes. To create multiple plans a full and 
empty bladder pretreatment CT scan is acquired from which 
a patient specific motion model is derived which is used to 
create intermediate target volume structures.  
In rectum cancer, however, shape changes are mostly driven 
by changes in rectum volume and shape and to a much lesser 
extent by bladder filling. Because of this creating multiple 
plans based on varying bladder filling is not useful. Therefor 
our strategy to create multiple plans for plan selection is to 
apply different PTV margins to the ventral side of the 
mesorectum based on a single CT scan. This will also coop 
with the shape changes that are encountered.  
Plan selection based on daily Conebeam CT (CBCT) images 
require adequate visibility of the regions of interest. In the 
pelvic region CBCT image quality can be hampered by 
imaging artefacts caused by moving air or bowel. At the same 
time identifying the boundaries of a complex target volume 
such as the target volume for rectum cancer can be 
challenging. Uniform plan selection is realized by 
participation in an observer study where all observers 
